Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2018
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2018
SUMMARY
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 10 molecules. The latest report Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 1, 2 and 1 respectively. Report covers products from therapy areas Respiratory, Dermatology, Immunology, Central Nervous System, Ear Nose Throat Disorders and Ophthalmology which include indications Asthma, Androgenic Alopecia, Chronic Obstructive Pulmonary Disease (COPD), Allergic Asthma, Allergic Rhinitis, Allergic Rhino-Conjunctivitis, Allergies, Inflammation and Nasal Polyps (Nasal Polyposis).
Furthermore, this report also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 10 molecules. The latest report Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 1, 2 and 1 respectively. Report covers products from therapy areas Respiratory, Dermatology, Immunology, Central Nervous System, Ear Nose Throat Disorders and Ophthalmology which include indications Asthma, Androgenic Alopecia, Chronic Obstructive Pulmonary Disease (COPD), Allergic Asthma, Allergic Rhinitis, Allergic Rhino-Conjunctivitis, Allergies, Inflammation and Nasal Polyps (Nasal Polyposis).
Furthermore, this report also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)
- The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Overview
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development
Allergan Plc
Brickell Biotech Inc
Idorsia Pharmaceutical Ltd
KBP BioSciences Co Ltd
Merck & Co Inc
Novartis AG
Oxagen Ltd
Pulmagen Therapeutics LLP
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles
ACT-774312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADC-3680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-5000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-7026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize PTGDR2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Timapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Products
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Product Development Milestones
Featured News & Press Releases
Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma
Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma
Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers
Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis
Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease
Feb 18, 2015: The US FDA approved KBP-7026 to enter Phase I clinical trial
Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study
Aug 01, 2014: Eleventa has enrolled first patients in Phase III multicenter clinical trial
Jul 28, 2014: Eleventa enrolled the first patients into the multi-center center clinical study of the 3rd phase of anti-asthmatic drug
Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma
Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis
May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis
Nov 20, 2012: Eleventa has become a Skolkovo resident
Sep 19, 2012: Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen’s Drug Candidate for Asthma Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Overview
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development
Allergan Plc
Brickell Biotech Inc
Idorsia Pharmaceutical Ltd
KBP BioSciences Co Ltd
Merck & Co Inc
Novartis AG
Oxagen Ltd
Pulmagen Therapeutics LLP
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles
ACT-774312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADC-3680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBI-5000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-7026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize PTGDR2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Timapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Products
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Product Development Milestones
Featured News & Press Releases
Dec 14, 2016: Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma
Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma
Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers
Feb 17, 2016: Update on Phase 2 clinical trial with OC459 in patients with moderate to severe atopic dermatitis
Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss
Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease
Feb 18, 2015: The US FDA approved KBP-7026 to enter Phase I clinical trial
Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study
Aug 01, 2014: Eleventa has enrolled first patients in Phase III multicenter clinical trial
Jul 28, 2014: Eleventa enrolled the first patients into the multi-center center clinical study of the 3rd phase of anti-asthmatic drug
Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma
Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis
May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis
Nov 20, 2012: Eleventa has become a Skolkovo resident
Sep 19, 2012: Maxwell Biotech Venture Fund Invests in Pivotal Clinical Trial of Oxagen’s Drug Candidate for Asthma Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Allergan Plc, H2 2018
Pipeline by Brickell Biotech Inc, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by KBP BioSciences Co Ltd, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Oxagen Ltd, H2 2018
Pipeline by Pulmagen Therapeutics LLP, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Allergan Plc, H2 2018
Pipeline by Brickell Biotech Inc, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by KBP BioSciences Co Ltd, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Oxagen Ltd, H2 2018
Pipeline by Pulmagen Therapeutics LLP, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Allergan Plc
Brickell Biotech Inc
Idorsia Pharmaceutical Ltd
KBP BioSciences Co Ltd
Merck & Co Inc
Novartis AG
Oxagen Ltd
Pulmagen Therapeutics LLP
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Allergan Plc
Brickell Biotech Inc
Idorsia Pharmaceutical Ltd
KBP BioSciences Co Ltd
Merck & Co Inc
Novartis AG
Oxagen Ltd
Pulmagen Therapeutics LLP
